Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
PGF2alpha Agonists Market: Competitive Landscape, Pipeline, and Market Analysis 2022
PGF2alpha Agonists Market: Competitive Landscape, Pipeline, and Market Analysis 2022
PGF2α (Prostaglandin F2α) is a prostaglandin E2 and F2α receptor agonist, which is formed by the reduction of PGH2 by PG endoperoxide synthase or reductase. PGF2α acts by binding to the prostaglandin F2α receptor. It is released in response to an increase oxytocin levels in the uterus and stimulates both luteolytic activity and the release of oxytocin. In pregnancy, PGF2α is medically used as an abortifacient to sustain contracture and provoke myometrial ischemia to accelerate labor and prevent significant blood loss in labor, which act by stimulating uterine muscle contractions. PGF2α agonists are also predominantly used for the treatment of open-angle glaucoma and ocular hypertension, where they act either by reducing intra-ocular pressure or by increasing uveoscleral outflow. AbbVie, Santen, AGC Biologics, Aerie Pharma, and Merck (MSD) are some of the key players of PGF2α agonists in the market.
Key Developments:
Approved PGF2α Agonist
Drugs under the Pipeline for PGF2α Agonists
Clinical Activity and Development of PGF2α Agonists
In the PGF2α agonists market,currently, there are more than 30 products being marketed and developed by 22 pharmaceutical companies, including both approved drugs and drugs in clinical trials.
|
Molecule Name |
Number of Studies |
|
Sepetaprost (DE-126) |
9 |
|
Latanoprost ocular implant (PA5108) |
6 |
|
Travoprost punctal plug (OTX-TP) |
4 |
|
Bimatoprost ophthalmic (T4032) |
3 |
|
Tatanoprost liposomal (POLAT 001) |
3 |
|
Travoprost intracameral implant (AM008) |
3 |
|
Catioprost (latanoprost emulsion) |
2 |
|
Medidur (Fluocinolone acetonide micro-insert intravitreal implant) |
2 |
|
Rescula (Unoprostone isopropyl) |
2 |
|
Dorzolamide/Latanoprost (ALZ-1101) |
2 |
|
Latanoprost/Dorzolamide (CKD-351) |
2 |
|
Trabodenoson/Latanoprost |
2 |
|
AGN-193408 |
1 |
|
Bimatoprost/Brimonidine |
1 |
|
Latanoprost/Timolol (T2347) |
1 |
|
Subconjunctival Latanoprost Insert (VS-101) |
1 |
|
Travoprost (ENV-515) |
1 |
PGF2α agonists, including latanoprost, travoprost, and bimatoprost are commonly used in the treatment of glaucoma. These medications help reduce intraocular pressure by increasing the outflow of aqueous humor from the eye. Similar to glaucoma, PGF2α agonists are also prescribed for management of ocular hypertension. Elevated intraocular pressure, without signs of glaucomatous damage, can be treated with these medications to prevent the development of glaucoma. Some PGF2α agonists, such as bimatoprost, have been investigated for their potential use in the treatment of cystoid macular edema, a condition characterized by fluid accumulation in the macula of the eye. Certain PGF2α agonists, such as gemeprost, can be used in combination with mifepristone to induce medical abortion, which helps in the termination of early pregnancies.
AbbVie’s Lumigan had total sales of US$ 514 million in the year 2022, with US$ 242 million of product sales in the USA only. Nicox S.A. maintains patents for Vyzulta, and the U.S. Patent and Trademark Office recently determined that three USA composition of matter patents covering latanoprostene bunod are eligible for patent term extension, potentially through 2030. According to the first World Report on Vision issued by the World Health Organization, globally, at least 2.2 billion people have a vision impairment or blindness, of whom at least 1 billion have a vision impairment that could have been prevented or has yet to be addressed. Moreover, according to a study report, globally, the number of prevalent cases of glaucoma was 38,81,624 in 1990 and increased to 74,73,400 in 2019, while the age-standardized prevalence rate decreased from 119.92% in 1990 to 94.68% in 2019. Additionally, the prevalence of primary open-angle glaucoma is highest in Africa and the prevalence of primary angle-closure glaucoma is highest in Asia.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Vyzulta (Latanoprostene bunod ophthalmic solution), Rocklatan (Netarsudil and Latanoprost ophthalmic solution), Travatan (Travoprost), Lumigan (Bimatoprost ophthalmic solution), Durysta (Bimatoprost implant), Taptiqom (Tafluprost and Timolol), Zioptan (Tafluprost) are the approved PGF2? agonists.
The global sale of Lumigan for 2022 was US$ 514 million.
AbbVie, Santen, AGC Biologics, Aerie Pharma, and Merck (MSD) are a few major players in the PGF2alpha agonist space.
Open-angle glaucoma, Ocular hypertension, cystoid macular edema, and for abortifacient PGF2alpha agonists can be used.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.